JP2005508829A5 - - Google Patents

Download PDF

Info

Publication number
JP2005508829A5
JP2005508829A5 JP2001585782A JP2001585782A JP2005508829A5 JP 2005508829 A5 JP2005508829 A5 JP 2005508829A5 JP 2001585782 A JP2001585782 A JP 2001585782A JP 2001585782 A JP2001585782 A JP 2001585782A JP 2005508829 A5 JP2005508829 A5 JP 2005508829A5
Authority
JP
Japan
Prior art keywords
use according
apoptotic
cells
patient
blood cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001585782A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005508829A (ja
Filing date
Publication date
Priority claimed from CA 2309417 external-priority patent/CA2309417A1/en
Application filed filed Critical
Publication of JP2005508829A publication Critical patent/JP2005508829A/ja
Publication of JP2005508829A5 publication Critical patent/JP2005508829A5/ja
Withdrawn legal-status Critical Current

Links

JP2001585782A 2000-05-25 2001-05-25 内皮機能障害の治療における使用のためのアポトーシス体 Withdrawn JP2005508829A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA 2309417 CA2309417A1 (en) 2000-05-25 2000-05-25 Apoptotic entities for use in treatment of endothelium dysfunction disorders
PCT/CA2001/000760 WO2001089538A2 (en) 2000-05-25 2001-05-25 Apoptotic entities for use in treatment of endothelium dysfunction disorders

Publications (2)

Publication Number Publication Date
JP2005508829A JP2005508829A (ja) 2005-04-07
JP2005508829A5 true JP2005508829A5 (https=) 2008-07-10

Family

ID=4166242

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001585782A Withdrawn JP2005508829A (ja) 2000-05-25 2001-05-25 内皮機能障害の治療における使用のためのアポトーシス体

Country Status (6)

Country Link
US (2) US7279156B2 (https=)
EP (1) EP1289536A2 (https=)
JP (1) JP2005508829A (https=)
AU (1) AU6198801A (https=)
CA (1) CA2309417A1 (https=)
WO (1) WO2001089538A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2309518A1 (en) * 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
CA2309424A1 (en) * 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
CA2309417A1 (en) * 2000-05-25 2001-11-25 Anthony E. Bolton Apoptotic entities for use in treatment of endothelium dysfunction disorders
US20030211548A1 (en) * 2002-01-29 2003-11-13 Oncolmmunin, Inc. Visualization and quantitiation of cellular cytotoxicity using cell-permeable fluorogenic protease substrates and caspase activity indicator markers
EP3500277A4 (en) * 2016-08-19 2020-04-15 Immunores-Therapeutics, LLC RELEASE SYSTEMS AND METHODS FOR GAS TREATMENT
US20210393990A1 (en) * 2020-06-17 2021-12-23 Donald Murrill BOTTA, JR. Ultrasound therapy for systemic immune modulation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696092B2 (en) * 1992-02-07 2004-02-24 Vasogen Ireland Limited Endothelial lining effects and treatment of vasospastic disorders
AU3506293A (en) * 1992-02-07 1993-09-03 Anthony Ernest Bolton Method of inhibiting the aggregation of blood platelets
US5980954A (en) * 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
DE69629436T2 (de) 1995-05-05 2004-06-17 Vasogen Ireland Ltd., Shannon Wirkungen auf der endothelauskleidung und behandlung von vasospastischen erkrankungen
JP2002514408A (ja) 1998-05-11 2002-05-21 インセルム(アンスティチュ・ナショナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) 新規アポトーシス小体、それを含有する単球由来細胞、それらの調製方法、及びワクチンとしてのそれらの使用
ATE233093T1 (de) * 1998-11-13 2003-03-15 Vasogen Ireland Ltd Arzneimittel zur vermeidung und umkehrung der atherosklerose bei säugetieren
CA2269364A1 (en) 1999-04-19 2000-10-19 Vasogen Ireland Limited Treatment of inflammatory and allergic disorders
CA2271190A1 (en) * 1999-05-06 2000-11-06 Vasogen Ireland Limited Improved method for treating mammals with modified mammalian blood
CA2309417A1 (en) * 2000-05-25 2001-11-25 Anthony E. Bolton Apoptotic entities for use in treatment of endothelium dysfunction disorders
US7122208B2 (en) * 2001-04-06 2006-10-17 Vasogen Ireland Limited Compositions containing apoptotic entities
US7255880B2 (en) * 2003-04-03 2007-08-14 Vasogen Ireland Limited Treatment of endothelin-related disorders

Similar Documents

Publication Publication Date Title
JP2004522714A5 (https=)
JP2010047609A (ja) Mcp−1プロテインの軽減生産に活性な薬剤組成物
FR2798065B1 (fr) Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson
JP2002528502A5 (https=)
CA2397200A1 (en) Use of relaxin to treat diseases related to vasoconstriction
JP2001510795A5 (https=)
JP2015524444A5 (https=)
JP2003534281A5 (https=)
FI4104824T3 (fi) Koostumus käytettäväksi ylipainon ja liikalihavuuden hoitomenetelmässä potilailla, joilla on suuri sydän- ja verisuonitaudin riski
JP2004537500A5 (https=)
JP2005508829A5 (https=)
JP2002534479A5 (https=)
Kramer et al. Pulmonary valve vegetations detected with echocardiography
JP2002523437A5 (https=)
JP2004519424A5 (ja) インシュリン分泌促進剤およびHMG−Co−Aレダクターゼ阻害剤およびACE阻害剤から選択される活性成分を含む組み合わせ
JP2003534282A5 (https=)
Zein Interferons in the management of viral hepatitis
WO2001089537A3 (en) Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
RU2006101061A (ru) Азенапин для лечения шизофрении у пациентов с избыточной массой тела или предрасположенностью к избыточной массе тела
RU98111152A (ru) Применение активного вещества флупиртина или его фармакологически приемлемых солей в качестве лекарственного средства для профилактики и лечения заболеваний, ассоциированных с повреждением клеточной системы гемопоэза
Thijs et al. Why is antihypertensive drug therapy needed in elderly patients with systolodiastolic hypertension?
RU2008109165A (ru) Применение скелета клеточной стенки nocardia rubra для получения лекарства против вируса папилломы человека (hpv)
JP2002529515A5 (https=)
Bhugra et al. Antidepressant and cognitive behavior therapy for an AIDS patient.
JP2002325828A5 (https=)